Avra Labs secures CDSCO nod to manufacture, market Favipiravir API

Published On 2020-07-28 06:41 GMT   |   Update On 2020-07-28 06:41 GMT
Advertisement

Hyderabad: Avra Laboratories Pvt Ltd, a city based pharma company, has been granted regulatory approval by the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Favipiravir API, which will help patients suffering from COVID-19.

The company, in a press release, said it has developed an alternative low cost and highly efficient manufacturing process and is now supplying commercial quantities to drug maker Cipla for the launch of Ciplenza, the generic version of Favipiravir.

Advertisement

A V Rama Rao, Chairman, Avra Laboratories said, "I am very pleased to be working with Cipla and Dr Yusuf Hamied again, with whom I share a five-decade long association and friendship, during which time we collaborated on several projects to produce life saving drugs, including anti-cancer, anti-HIV/AIDS and several other generic products. The current pandemic has brought us together to work tirelessly for the speedy launch of Favipiravir", Rama Rao, a former director of CSIR-IICT founded Avra Laboratories, said.

Read also: Cipla to soon unveil COVID drug Ciplenza for Rs 68




Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News